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Vaccination has become an important and effective public-health measure for safeguard-
ing against devastating outcomes of infectious diseases. Current vaccines rely on the use 
of either attenuated (weakened) or killed strains of pathogens, e.g. against diphtheria, 
tetanus, measles and mumps. For some vaccines, such as the one against human smallpox, 
a strain from a different species (cowpox) is used instead. Some of these vaccines (espe-
cially parenteral vaccines) contain toxic preservatives such as formaldehyde, thiomersal 
(a mercury-based compound), and aluminum phosphate (Buetow and Korban, 000; 
Streatfield and Howard, 003). In recent years there has been a move towards developing 
subunit vaccines, linear immunogenic epitopes of the pathogen that elicit production of 
antibodies. This alleviates concerns over risk of reversion of attenuated strains to aggressive 
forms in pathogen-based vaccines (Buetow and Korban, 000). Scale-up production of 
current vaccines takes place either in specific pathogen-free (SPF) eggs or in mammalian 
cells grown in large fermentors or bioreactors. Therefore, these vaccines require purification 
before they are available for use. Moreover, most are delivered via intramuscular injection, 
and, therefore, require the use of sterile hypodermic needles.
In the last several years, a novel approach for developing subunit vaccines has emerged 
as a result of the genetic engineering technology: the use of plants as hosts—biological 
bioreactors. At this time, the most economical and technically feasible class of products 
using this approach involves the engineering of genes to express novel proteins. This has 
resulted in a $0-billion industry of new therapeutics and industrial enzymes (Howard, 
005).
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Opportunities
The important features of any effective vaccine include safety, protective immunity that 
is sustained for long periods of time (preferably a lifetime), stability, ease of administra-
tion, low cost and few side-effects. In recent years, plants have emerged as alternative 
production systems for subunit vaccines as they are likely to contribute to all of these 
critical features of effective vaccines. Plants that have been engineered with genes encoding 
antigenic proteins of various pathogenic viral and bacterial organisms have been shown 
to correctly express the proteins that elicit production of antibodies in mammalian hosts. 
Plants can readily and properly handle the downstream processing of foreign proteins, 
including expression, folding, assembly, and glycosylation, all contributing to the fidelity 
of antigenic proteins (Wycoff, 005). As a result, these proteins maintain their activity 
and efficacy, thus contributing to their viability as subunit-vaccine candidates (Figure ). 
Plants can produce not only single, simple foreign proteins, but also complex multimeres, 
such as secretory proteins and antibodies (Wycoff, 005). All these capabilities render 
Figure . Subunit-vaccine candidates against human and animal diseases for possible 
production in various crops.
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plants as targets of opportunity for marketing of high-value protein products. However, 
that’s not all that plants have to offer. 
Plant systems do not harbor human or animal pathogens (such as virions or prions) 
and, therefore, they do not transmit such pathogens along with the target subunit vac-
cine. Moreover, they cost less to produce than via fermentation or bioreactors; plants can 
be grown in the field or in a greenhouse relatively inexpensively (Howard, 005). When 
produced in edible parts of the plant, such as grain, fruit or even leaves, subunit vaccines 
may not require purification. Maintaining the antigenic protein within plant cells that 
are edible may also contribute to stability and reduce degradation. Another advantage 
of producing subunit vaccines in edible parts of a plant is the potential to deliver them 
orally rather than intramuscularly (Streatfield and Howard, 003), providing a simple and 
easy means of administration to humans and animals. Moreover, oral delivery stimulates 
mucosal immunity (the first line of defense) in the tissues lining the mouth, nose and 
esophagus (among others) that provide the first target of opportunity for pathogens to 
enter and infect the human body. In addition, production in plants reduces the overall 
cost of vaccinations, which is often prohibitive in developing countries; for example, 
sterile hypodermic syringes are not required.
The advantages and opportunities from producing subunit vaccines in plants may be 
summarized as follows:
• Elimination of risk of contamination with infectious agents
• With oral delivery, they activate the mucosal immune system—the first line of 
defense
• Avoidance of injections
 – Improved patient compliance
 – reduced risk of transmission of other infectious agents through contaminated 
needles
• Longer shelf-life
• Cost-effective in large quantities
However, myriad challenges are yet to be overcome before the promise of this technol-
ogy will be fully realized.
Challenges
The challenges facing plant-based-vaccine development include technical, regulatory and 
economic aspects and public perception. Among the technical challenges it is critical to 
select a plant system that can be grown under conditions that minimize environmental 
risks, such as transfer of pollen from transgenic to conventional varieties or to related 
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species. Expression of antigens in plants is a major regulatory concern. Whether or not 
the protein is confined to specific tissues will enable or nullify exposure to the environ-
ment. targeting expression via a tissue-specific promoter driving the transgene may 
reduce regulatory concerns (Korban, 00). For example, elimination of expression of 
the transgene in pollen will reduce dissemination of the antigenic protein to other plants 
and alleviate environmental contamination, although not completely.
Among other technical challenges to be considered, the crop should provide ample 
biomass for accumulation of a sufficient quantity of the antigenic protein. Whether it is a 
grain, vegetable or fruit crop, protocols will be needed to ensure transcription, translation, 
intracellular localization, tissue specificity, adequate gene-copy number, and metabolism 
and accumulation of the protein of interest (Buetow and Korban, 000; Streatfield and 
Howard, 003). Determining the level of expression of the transgene and stability of 
expression over generations of the transgenic line will be essential for determining the 
economic feasibility of a proposed plant-based vaccine. Depending on the target protein 
product, levels of 0 mg/kg of plant dry weight of a crop may be sufficient, although levels 
of 00 mg/kg or higher are more likely to be necessary (Howard, 005). Approximately 
50 kg per year of a particular antigenic protein would certainly meet economic feasibil-
ity. Other issues related to technical challenges include formulation: will the vaccine be 
marketed as an encapsulated powder, a concentrated liquid or a nasal aerosol? By what 
route will it be delivered? What will be the proper dosage? Would a single dosage suffice, 
or will (a) booster(s) be necessary? All of these technical questions are yet to be answered 
for plant-based vaccines.
Among regulatory challenges, issues relevant to any genetically modified (GM) crop 
that have to gain regulatory approval from the USDA, FDA and/or EPA apply to plant-
based vaccines. In addition, issues related to separation of a pharmaceutical product from 
the original crop targeted for the food chain have become increasingly important as con-
cerns over adventitious presence of medicinal products in the food supply have surfaced 
in recent years. Physical separation of dual-purpose crops is needed—whether achieved 
by geographical isolation or by greenhouse containment—as is dedicated equipment for 
harvesting and handling, as well as standardized monitoring procedures. Concerns over 
the use of food crops for production of plant-based vaccines have been accompanied with 
calls for targeting non-food crops for pharmaceutical purposes, whether for the production 
of therapeutic proteins or plant-based vaccines. However, as indicated above, food crops 
remain highly desirable as targets for production of plant-based vaccines because of their 
amenability for oral delivery, avoiding the necessity for isolation and purification of the 
subunit vaccine prior to delivery. In addition, regulatory issues related to clinical trials, 
going through phase I–IV trials—similar to any other pharmaceutical product—must 
be pursued to assess efficacy, safety and reliability, followed by FDA approvals. For more 
than 30 years, live attenuated vaccines have been produced in SPF eggs, and success-
fully used to immunize infants and adults against common diseases such as measles and 
mumps. So, how can we take advantage of the regulatory history already established by 
the vaccine industry to push for plant-based vaccines?
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Expanding Markets
Until recently, the vaccine market was considered low-margin, but that is changing as 
technology advances and new diseases are being addressed with vaccines. Worldwide, 
the market is $ billion according to Peter Young, CEO of AlphaVax (research triangle 
Park, NC), which is developing viral-vector vaccines for HIV, malaria, Marburg virus 
and cancer, among others. At least one plant-based vaccine must prove to be an economic 
success story in order to pave the way for others to make it through to commercialization. 
This new technology may also serve as a platform for delivery of multiple antigens against 
several economically important diseases. This would certainly alleviate economic concerns 
over the plant-based vaccine approach, and boost its impact on the market.
Three years ago, the Partnering	 for	Global	Health	Forum [co-sponsored by the Bio-
technology Industry Organization (Washington, DC) and the Bill and Melinda Gates 
Foundation (Seattle)] brought together individuals from biotechnology companies, 
government agencies, foundations, and NGOs interested in pursuing biotechnology-
based solutions for overcoming malaria, tuberculosis, typhoid, cholera, dengue fever, 
river blindness, AIDS and other diseases that plague developing nations. This was the 
beginning of an ongoing process to match funding sources and biotech companies, and 
to influence legislation and the regulatory process to encourage drug development for 
impoverished markets. Many biotechnology laboratories currently have proven technol-
ogy and compounds ready for late-stage development, but lack funding to bring them 
to fruition to assist the individuals who need them. The message of the meeting was that 
funding from foundations, the government, and not-for-profit groups is available to further 
these efforts. Unfortunately, plant-based vaccines were not specifically spelled out in the 
announcement for request for proposals, although it was clear that this technology has 
great potential to help meet the goals of this major worldwide initiative. 
As for the issue of the public’s acceptance of plant-based vaccine technology, it is im-
portant to point out that the pharmaceutical industry has become a target for critics, and 
negative opinion is reflected in public polls. In a Kasier Family Foundation poll (spring 
005), pharmaceutical companies were ranked seventh in a list of nine industries, deemed 
less trustworthy than HMOs, but more trustworthy than oil and tobacco companies.
The pharmaceutical industry estimates that the cost of bringing a new chemical entity 
to market is around $800 million (including time-value of money; i.e., factoring in the 
interest a company has to pay to borrow capital). Therefore, it is deemed justifiable that 
the public pays more in order for these drug companies to see returns on their invest-
ments. This, in turn, has contributed to the public’s anger over drug prices. The shortage 
of influenza vaccine supply in the winter of 00–005 revived an issue that predates 
the biotech industry: what is the best way to make vaccines? For the influenza vaccine, a 
confluence of cost, pricing legal liability, and inertia provides an odd, but now familiar 
answer. Influenza vaccine is produced in chicken eggs, a manufacturing process blessed by 
regulatory bodies worldwide despite the fact that it has not been substantially upgraded in 
0 years. The plant-based technology may circumvent long-standing production problems 
inherent in the egg-based system.
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Summary
Producing vaccines in plants offers numerous advantages over current vaccine methodolo-
gies. Among them, safety, ease of production and low cost of production provide strong 
justification for developing the technology. However, many challenges remain within the 
pharmaceutical industry; requirements for generating non-food products in transgenic 
plants are different from those for food products. These challenges include technical, 
regulatory, economic, and public-perception issues. Physical isolation, delayed planting, 
agronomic support, dedicated equipment and frequent monitoring all contribute to the 
technical challenges involved. 
As the technology to produce vaccines in plants goes through the regulatory pathway 
and demonstrates its economic feasibility, it may also overcome public-perception con-
cerns that seem to have been dodged by the pharmaceutical industry. The likelihood that 
plant-based vaccines can be administered via oral or intranasal delivery systems will also 
add to their desirability as well as their economic benefits. There is potential for major 
impacts on global health, particularly in developing countries. However, standardized 
safety-assessment models must meet with approval from the general public along with the 
regulatory agencies and other interested parties. risk assessment must be science-based in 
order for the results to be believable and trustworthy. Funding of research will accelerate 
the advances made thus far, and bring this technology closer to commercialization and 
worldwide use. 
Producing	vaccines	in	plants	offers	numerous	advantages	over	
current	vaccine	methodologies.	However,	many	challenges	remain.
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